Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · IEX Real-Time Price · USD
15.14
+1.04 (7.38%)
May 3, 2024, 4:30 PM EDT - Market closed
Gyre Therapeutics Employees
Gyre Therapeutics had 593 employees on December 31, 2023. The number of employees increased by 586 or 8,371.43% compared to the previous year.
Employees
593
Change (1Y)
586
Growth (1Y)
8,371.43%
Revenue / Employee
$191,315
Profits / Employee
-$156,717
Market Cap
1.29B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 593 | 586 | 8,371.43% |
Dec 31, 2022 | 7 | -38 | -84.44% |
Dec 31, 2021 | 45 | -11 | -19.64% |
Dec 31, 2020 | 56 | 22 | 64.71% |
Dec 31, 2019 | 34 | 13 | 61.90% |
Dec 31, 2018 | 21 | 8 | 61.54% |
Dec 31, 2017 | 13 | 3 | 30.00% |
Dec 31, 2016 | 10 | -9 | -47.37% |
Dec 31, 2015 | 19 | 0 | - |
Dec 31, 2014 | 19 | -21 | -52.50% |
Dec 31, 2013 | 40 | 0 | - |
Dec 31, 2012 | 40 | -102 | -71.83% |
Dec 31, 2011 | 142 | 10 | 7.58% |
Dec 31, 2010 | 132 | 16 | 13.79% |
Dec 31, 2009 | 116 | 2 | 1.75% |
Dec 31, 2008 | 114 | 10 | 9.62% |
Dec 31, 2007 | 104 | 15 | 16.85% |
Dec 31, 2006 | 89 | 11 | 14.10% |
Dec 31, 2005 | 78 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Alignment Healthcare | 1,536 |
Pacira BioSciences | 712 |
Ironwood Pharmaceuticals | 267 |
4D Molecular Therapeutics | 147 |
Ligand Pharmaceuticals | 58 |
Akero Therapeutics | 56 |
Belite Bio | 20 |
GYRE News
- 5 weeks ago - Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum - GlobeNewsWire
- 2 months ago - INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Gyre Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm - Accesswire
- 3 months ago - IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Gyre Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm - Accesswire
- 3 months ago - INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Gyre Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm - Accesswire
- 3 months ago - SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Gyre Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm - Accesswire
- 5 months ago - Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding - PRNewsWire
- 6 months ago - Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting - GlobeNewsWire